Early trial tests Two-Pronged attack on tough tumors
NCT ID NCT06781125
Summary
This early-stage study is testing the safety of a new two-part treatment for advanced solid tumors. It combines a new drug, JCXH-211, injected directly into the tumor with an existing immunotherapy (anti-PD-1) given by IV. The goal is to see if this combination is safe and tolerable for patients whose cancer has progressed after standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.